Patient Compliance and Persistence with Anti-Hyperglycemic Therapy: Evaluation of a Population of Type 2 Diabetic Patients
Open Access
- 1 February 2002
- journal article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 30 (1), 71-79
- https://doi.org/10.1177/147323000203000111
Abstract
The persistence and compliance of type 2 diabetic patients to different regimens of anti-hyperglycemic therapy were assessed retrospectively. The pharmacy claims from a pharmacy benefit management organization were analysed from the third quarter of 1996 to the fourth quarter of 1999. Of the 23 400 patients enrolled and initiating anti-diabetic therapy, 85% started treatment with monotherapy, 9.5% with insulin alone, 4.1% with polytherapy and 1.3% with insulin plus another therapy. Monotherapy patients were characterized as receiving metformin, sulfonylurea or another agent. For the 1-year follow-up period, 70.5% of the metformin patients, 75.3% of the sulfonylurea patients and 86.8% of the polytherapy patients underwent no regimen modification (except discontinuation). For the patients who had no modification of their medication regimen, persistence with sulfonylurea or metformin monotherapy was 65% greater than with polytherapy over a 1-year period. Compliance with sulfonylurea or metformin monotherapy was 45% greater than with polytherapy.Keywords
This publication has 5 references indexed in Scilit:
- Diabetes trends in the U.S.: 1990-1998.Diabetes Care, 2000
- Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.Diabetes Care, 1999
- Economic Consequences of Diabetes Mellitus in the U.S. in 1997Diabetes Care, 1998
- Health Care for Elderly Persons — Myths and RealitiesNew England Journal of Medicine, 1995
- Facilitating Treatment AdherencePublished by Springer Science and Business Media LLC ,1987